NEW YORK (GenomeWeb News) – Immunodiagnostic Systems has licensed the right to use new biomarkers developed by Biosignatures for use in immunoassay diagnostic test kits for kidney diseases, IDS said today.
The agreement covers the proteomics-based biomarker technology developed by Biosignatures, a Newcastle, UK-based company that spun out from Nonlinear Dynamics. The initial focus of the license agreement will cover kidney diseases and related conditions and will use the IDS iSYS platform, IDS said.
IDS CEO Roger Duggan said in a statement that Biosignatures has "an enlightened approach to proteomics based upon extensive hard-headed commercial experience."
Financial terms of the agreement were not released.